These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 17453371)

  • 21. Carboplatin/gemcitabine alternating with carboplatin/pegylated liposomal doxorubicin and carboplatin/cyclophosphamide in platinum-refractory/resistant paclitaxel - pretreated ovarian carcinoma.
    Pectasides D; Pectasides E; Papaxoinis G; Psyrri A; Pliarchopoulou K; Koumarianou A; Macheras A; Athanasas G; Xiros N; Economopoulos T
    Gynecol Oncol; 2010 Jul; 118(1):52-7. PubMed ID: 20406710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of neoadjuvant gemcitabine, pegylated liposomal doxorubicin, and docetaxel in locally advanced breast cancer.
    Artioli G; Mocellin S; Borgato L; Cappetta A; Bozza F; Zavagno G; Zovato S; Marchet A; Pastorelli D
    Anticancer Res; 2010 Sep; 30(9):3817-21. PubMed ID: 20944176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer.
    Rom J; Bechstein S; Domschke C; Golatta M; Mayer C; Heil J; Thum J; Smetanay K; Windemuth-Kieselbach C; Wallwiener M; Marme F; Schuetz F; Sohn C; Schneeweiss A
    Anticancer Drugs; 2014 Feb; 25(2):219-24. PubMed ID: 24247203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study.
    Rau KM; Lin YC; Chen YY; Chen JS; Lee KD; Wang CH; Chang HK
    BMC Cancer; 2015 May; 15():423. PubMed ID: 25994543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma.
    Pectasides D; Xiros N; Papaxoinis G; Aravantinos G; Sykiotis C; Pectasides E; Psyrri A; Koumarianou A; Gaglia A; Gouveris P; Economopoulos T
    Gynecol Oncol; 2008 Jan; 108(1):47-52. PubMed ID: 17915300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of advanced breast cancer with gemcitabine and vinorelbine plus human granulocyte colony-stimulating factor.
    Haider K; Kornek GV; Kwasny W; Weinländer G; Valencak J; Lang F; Püribauer F; Kovats E; Depisch D; Scheithauer W
    Breast Cancer Res Treat; 1999 Jun; 55(3):203-11. PubMed ID: 10517165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer.
    Rivera E; Valero V; Syrewicz L; Rahman Z; Esteva FJ; Theriault RL; Rosales MM; Booser D; Murray JL; Bast RC; Hortobagyi GN
    J Clin Oncol; 2001 Mar; 19(6):1716-22. PubMed ID: 11251001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial.
    Schmid P; Krocker J; Jehn C; Michniewicz K; Lehenbauer-Dehm S; Eggemann H; Heilmann V; Kümmel S; Schulz CO; Dieing A; Wischnewsky MB; Hauptmann S; Elling D; Possinger K; Flath B
    Ann Oncol; 2005 Oct; 16(10):1624-31. PubMed ID: 16030028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I-II study on a gemcitabine-cyclophosphamide-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients.
    Frasci G; D'Aiuto G; Comella P; Thomas R; Capasso I; Botti G; Cortino GR; Di Bonito M; Rubulotta R; Vallone P; Comella G
    Oncology; 2002; 62(1):25-32. PubMed ID: 11810040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study).
    Fujiwara H; Ushijima K; Nagao S; Takei Y; Shimada M; Takano M; Yoshino K; Kawano Y; Hirashima Y; Nagase S; Nishio S; Nishikawa T; Ito K; Shoji T; Kimura E; Takano T; Sugiyama T; Kigawa J; Fujiwara K; Suzuki M
    Int J Clin Oncol; 2019 Oct; 24(10):1284-1291. PubMed ID: 31127479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer. Final results from a phase II trial.
    Sánchez-Rovira P; Jaén A; González E; Porras I; Dueñas R; Medina B; Mohedano N; Fernández M; Martos M; Lozano A; Carrasco E
    Oncology (Williston Park); 2001 Feb; 15(2 Suppl 3):44-7. PubMed ID: 11252890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial.
    Schmid P; Krocker J; Schulz CO; Michniewicz K; Dieing A; Eggemann H; Heilmann V; Blohmer JU; Sezer O; Elling D; Possinger K
    Anticancer Drugs; 2005 Jan; 16(1):21-9. PubMed ID: 15613900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer.
    Rocca A; Maltoni R; Passardi A; Massa I; Aquilina M; Ridolfi R; Ibrahim T; Cecconetto L; Sarti S; Pietri E; Nanni O; Amadori D
    Cancer Chemother Pharmacol; 2010 Apr; 65(5):871-6. PubMed ID: 19693503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
    Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
    BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).
    Sehouli J; Chekerov R; Reinthaller A; Richter R; Gonzalez-Martin A; Harter P; Woopen H; Petru E; Hanker LC; Keil E; Wimberger P; Klare P; Kurzeder C; Hilpert F; Belau AK; Zeimet A; Bover-Barcelo I; Canzler U; Mahner S; Meier W
    Ann Oncol; 2016 Dec; 27(12):2236-2241. PubMed ID: 27789470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure.
    Demiray M; Kurt E; Evrensel T; Kanat O; Arslan M; Saraydaroglu O; Ercan I; Gonullu G; Gokgoz S; Topal U; Tolunay S; Tasdelen I; Manavoglu O
    Cancer Invest; 2005; 23(5):386-91. PubMed ID: 16193637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclophosphamide, doxorubicin, and gemcitabine combination chemotherapy for treatment of metastatic and locally advanced breast cancer.
    Levin M; Durgam S; Novetsky A
    Cancer Invest; 2002; 20(7-8):872-5. PubMed ID: 12449716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gemcitabine and anthracyclines in breast cancer.
    Jassem J
    Semin Oncol; 2003 Apr; 30(2 Suppl 3):11-4. PubMed ID: 12722019
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
    Stickeler E; Klar M; Watermann D; Geibel A; Földi M; Hasenburg A; Gitsch G
    Breast Cancer Res Treat; 2009 Oct; 117(3):591-8. PubMed ID: 19156515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II trial of vinorelbine and pegylated liposomal doxorubicin in patients with pretreated metastatic breast cancer.
    Chow LW; Yip AY; Lang BH
    Am J Clin Oncol; 2007 Apr; 30(2):133-8. PubMed ID: 17414461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.